LATEST NEWS AND EVENTS

Oncidium Spring NEWSLETTER

Fresh news about Oncidium and Radiotheranostics, close up on Neuroendocrine Cancer UK, meet the Oncidium Ambassadors and much more! >> Discover the Newsletter  

Covid19 – Stay safe

Today, we would like to raise awareness of a different nature, equally important. We hope your relatives and you are well and healthy. The...

The Oncidium foundation goes live !

After six months of hard labor, research and discussions, welcome to the Oncidium’s new website! The entire website has been face-lifted in a user-friendly way...

World Cancer Day

The 4th of February is the World Cancer Day. Let's increase opportunities to build global awareness and impact-driven action. Keep strong, keep believing, keep...

EANM FOCUS MEETING – Theranostics for NET’s

Event: EANM FOCUS 3 - Molecular Imaging and Theranostics in Neuroendocrine tumours Date: Jan 30 - Feb 01, 2020 Location: Athens, Greece In-depth overview of the latest...

Radiolabeled PSMA PET for Renal Cancer

Promising results regarding the role of Radiolabeled PSMA PET as an imaging modality for the evaluation of widespread disease and response to target and...

How Radiotheranostics work?

Still wondering how Radiotheranostics work? Read this very interesting and accessible article by the International Atomic Energy Agency (IAEA):“It is a very efficient approach...

Strong potential of targeted α-therapy with 225Ac-PSMA-617

Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. Dr. Machaba Michael Sathekge comments the...

Merry Christmas and Happy New Year

What a year! Looking back at 2019, we were able to start The Oncidium foundation activities, build a motivated team, meet wonderful dedicated people...

ARAB HEALTH 2020

Event: Arab Health 2020 Date: 27 - 30 January 2020 Location: UAE - Dubai World Trade Center Contact: tala@oncidium-life.org

Happy Thanksgiving

This year, Oncidium has a lot to be thankful for! We have been able to start our activities around the promotion of Radiotheranostics. First...

Promising results for prostate cancer response to PRLT

First promising results on a pilot experience suggest that a single course of tandem therapy with low-activity 225Ac-PSMA-617/full-activity 177Lu-PSMA-617 may safely enhance response to...

A dedicated Oncidium’s Ambassador at ALASBIMN 2019

We could not have missed the XXVII Congress of ALASBIMN 2019 in Lima, Peru! Such an important congress at the regional level that brings...

EANM commitment: learning from the UK experience

Patient/public involvement and engagement (PPI/PE) incorporates and integrates individual’s perspectives in the planning and improvement of healthcare services and research: “No matter how complicated...

CONNECT WITH US

2 days ago
Education is key! #Oncidiumfoundation provides accessible & up-to-date information about marketed products, ongoing clinical trials, early stage… for a better understanding of the functioning & benefits of #Radiotheranostics for #cancercare.
Learn more:
https://t.co/UNnFWp2DkZ https://t.co/wwFWSccBFY
1 week ago
1st article in collaboration with @DOTmedcom. Discover more about how #Radiotheranostics continue to gain momentum. Special thanks to MEDraysintell for the figures on the global #nuclearmedicine market.
#oncidiumfoundation #promotingtheranostics

https://t.co/eloEJQd9zI
2 weeks ago
This week is #EWAC2020 Each day will focus on one aspect of the cancer continuum: primary prevention, early detection, cancer research, access to treatments, patients & survivors & care infrastructure.
Check out the @CancerLeagues work towards improved cancer control & care. https://t.co/Ald6ZEozHE